Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?

Merck (MRK) stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and provided a disappointing guidance for 2025.On Feb. 4, Merck announced its fourth-quarter and full-year 2024 results. While the drug giant beat estimates for both earnings and sales, its financial outlook for 2025, provided along with the earnings release, fell short of investor expectations.Sales of human papillomavirus vaccine, Gardasil, which is Merck’s second largest product, dec ...